非布司他的价格

Price: The domestic price of febuxostat is RMB 10 per tablet, 40mg/tablet. The recommended dosage of febuxostat is 40mg/day, which means that febuxostat costs about 300 yuan per month. The Indian version of Febuxostat is produced by Zydus Pharmaceuticals in India. Its efficacy is the same as that of the original drug, but the price is much lower. The specification is 80mg*30 tablets/box, and its price is about $200. It is currently the most cost-effective drug.

Febuxostat is a xanthine oxidase (XO) inhibitor indicated for the long-term treatment of hyperuricemia with gout symptoms. This product is not recommended for the treatment of asymptomatic hyperuricemia. Gout is a common and complex type of arthritis. People of all ages may suffer from gout. Gout patients often experience sudden joint pain at night. The pain is quite high and feels like a big toe being burned. If not treated in time, the consequences of delay will be that the pain will become stronger and more unbearable. And it can also endanger other normal functions of the body.

Febuxostat applied for marketing in Japan in early 2004. In April 2008, the European Union first approved the marketing of febuxostat tablets, with specifications of 80 mg and 120 mg, and the trade name "Adenuric". It is used to treat chronic hyperuricemia with uric acid deposition (including patients with gout stones and/or gouty arthritis, or patients with a history of this). The FDA approved Febuxostat tablets for marketing in February 2009 for the long-term control of hyperuricemia in patients with gout. It was approved for sale in China in 2013. In the following years, it became the choice of more and more gout friends with its "better acid-lowering effect and higher safety".

It is a new type of non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has a high utilization rate. Food and antacids have no significant effect on its absorption. Unlike allopurinol, its structure is a non-purine analogue, so it is selective in inhibiting xanthine oxidase and has little effect on other enzymes in purine or pyrimidine metabolism. This means that febuxostat is less likely to be affected by other factors and has a stable effect.